Literature DB >> 2296362

Transient focal neurologic deficits complicating interleukin-2 therapy.

J T Bernard1, S Ameriso, R A Kempf, P Rosen, M S Mitchell, M Fisher.   

Abstract

We report 2 patients with transient, focal, repetitive, stereotyped episodes of neurologic deficits during treatment with interleukin-2. One patient had recurrent monocular blindness, while the 2nd had recurrent homonymous quadrantanopia. We suggest that these attacks are provoked by endothelial cell activation induced by interleukin-2.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2296362     DOI: 10.1212/wnl.40.1.154

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  6 in total

1.  Phase II study of low dose cyclophosphamide and intravenous interleukin-2 in metastatic renal cancer.

Authors:  W D Quan; G E Dean; G Lieskovsky; M S Mitchell; R A Kempf
Journal:  Invest New Drugs       Date:  1994       Impact factor: 3.850

Review 2.  Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.

Authors:  Ruth Whittington; Diana Faulds
Journal:  Drugs       Date:  1993-09       Impact factor: 9.546

3.  Neurotoxicity of antitumoral IL-2 therapy: evoked cognitive potentials and brain mapping.

Authors:  A Pace; A Pietrangeli; L Bove; M Rosselli; M Lopez; B Jandolo
Journal:  Ital J Neurol Sci       Date:  1994-10

4.  Delayed neurotoxicity of intraventricular interleukin-2: a case report.

Authors:  C A Meyers; W K Yung
Journal:  J Neurooncol       Date:  1993-03       Impact factor: 4.130

5.  In vivo relationship of interleukin-2 and soluble IL-2 receptor to blood-brain barrier impairment in patients with active multiple sclerosis.

Authors:  M K Sharief; R Hentges; M Ciardi; E J Thompson
Journal:  J Neurol       Date:  1993-01       Impact factor: 4.849

Review 6.  Clinical toxicity of interleukin-2.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.